NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled
NCT05005403 2025-10-28Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabAbbViePhase 1 Recruiting512 enrolled
NCT05039801 2025-10-14IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsM.D. Anderson Cancer CenterPhase 1 Recruiting54 enrolled